Former White House drug czar, in a recent interview, said that as the U.S. Food and Drug Administration under the Trump Administration prepared to propose federal regulations on kratom a number top officials intervened and criticized the agency’s bias, stopping it from proceeding with scheduling.
They did not provide–didn’t have–all the facts. “They didn’t know the science,” Jim Carroll said, who was director of the Office of National Drug Control Policy or drug czar under President Donald Trump between 2018 and 2021. “FDA didn’t paint the whole picture.” “They may not have had the whole picture, but others did.”
Carroll, a former lawyer who is now a consultant and private lawyer, made these comments in a conversation with Mac Haddow (senior fellow at the American Kratom Association, AKA) during the National Conference of State Legislatures Summit held earlier this month in Indianapolis.
A former White House official stated that around 2018, when the Trump administration was deciding whether or not to include kratom in the Controlled Substances Act the FDA made a presentation that misrepresented the drug’s potential benefits and risk profile.
The agency “talked about kratom as an opioid.” Carroll stated, “We know this is wrong. It’s flat out wrong.” “They said it was highly addictive.” Johns Hopkins and other independent medical researchers have stated that it is no more addictive than the cup of coffee I had in the morning before this interview.
Carroll initially said that he, along with others, were inclined to rely on FDA expertise. “I was sitting there thinking, ‘OK, this is the FDA, Food and Drug Administration. He recalled that they knew what they were talking about.
Carroll admitted that his office had little experience with kratom. He explained that kratom was not a drug already on the schedule. “So, it was not something our office had much experience with before coming into this.”
The FDA had planned to give a similar presentation to the Drug Enforcement Administration, “because it’s the agency that has to approve the production of a new controlled drug.”
Carroll reports that Brett Giroir was the Assistant Secretary of Health at the Department of Health and Human Services when he heard about the FDA’s claims. Carroll says that Brett Giroir told him to “don’t allow this to happen.” ‘”
Carroll also said that Nora Volkov (director of the National Institute on Drug Abuse, NIDA) was involved. Carroll said that together with other officials, they began to review available research and questioned the FDA’s positions.
Carroll stated, “We canceled the schedule on the spot.”
Carroll explained that Americans used kratom more as a substitute than as a substance to abuse.
He said, “It helps people who have an opioid addiction.” It works in the same area of the brain as opioids, which cause sedation and stop breathing.
Carroll said that a government study showed “that the vast majority of users are using kratom in the right way.” Carroll noted that “they’re using it a supplement – as a food if you like, because it is a tea-leaf.” They use it to stop taking opioids. “They’re doing what we are supposed to, which is to save lives.”
In 2010, more than 109,000 Americans were killed by drug overdoses. Synthetic opioids such as fentanyl were present in 75,000 of these cases.
Haddow, of AKA, pointed out that Carroll’s description was largely a secret. “When all of this was going on, there was absolutely zero transparency about what was happening,” he said. “The decision that was made by Dr. Giroir, that was to formally withdraw the recommendation–and the DEA had to withdraw it–wasn’t public for two and a half years.”
“Why does the FDA do this?” he asked. “What possibly would be their motivation, and why are they so hell-bent?”
“I don’t know why there’s an institutional bias–and that’s the word that I’m intentionally using–there is a bias against kratom,” Carroll replied. “All they have to do is follow the facts and they will realize that there’s actually great potential in this.”
“The only thing I can think of is their concern is, ‘Oh my gosh, we’re gonna let something happen, and we’re not on top of it. We’re going to look bad,'” he added. “And the reality is, they’re depriving people of this.”
Carroll argued that steps need to be taken to ensure that kratom sold in the U.S. is well-regulated, clearly labeled and lab-tested for potency and purity. He pointed out that many people dying from fentanyl overdoses don’t even know they’re taking the drug.
“They might be taking an opioid because of their addiction, because of pain, and they don’t realize there’s fentanyl in it,” said Carroll, whose daughter developed a substance use disorder after being prescribed opioids. “What they’re doing is they’re dying from a poisoning, because they’re not taking something that is safe.”
“Nothing else matters unless we’re truly making a meaningful difference in saving lives,” he said. “It’s time for states to go back and look at the science.”
A number of legislatures are doing exactly that as dozens of states weigh whether to regulate or outlaw kratom. Haddow noted that, so far, 11 states have passed a version of the Kratom Consumer Protection Act (KCPA), model legislation supported by the AKA. In some cases, lawmakers even rolled back bans on kratom products and instead embraced regulation.
Broadly speaking, the KCPA sets a minimum age of 18 to buy kratom products (though some states have made it 21), prohibits the addition of adulterants or “any synthetic or artificially elevated alkaloid content,” requires that manufacturers register with the proper regulatory authority and creates standards around packaging and labeling.
“There’s not too many industries that are asking for regulation these days, but the Kratom Association is, because they want to make sure that there’s proper labeling,” Carroll said. “They want to make sure it’s not an adulterated substance, that there’s not things being added to it that a consumer doesn’t know.”
Carroll is slated to speak on the topic again next week during an online Q&A session hosted by AKA. Also speaking at that event will be John Shinholser, co-founder and president of the drug recovery organization The McShin Foundation.
At the federal level, a trio of bipartisan lawmakers last year filed the Federal Clarity for Kratom Consumers Act, a first-of-its-kind bill that would have limited the restrictions that regulators at HHS could have set on kratom. At the time, sponsor Sen. Mike Lee (R-UT) said FDA “needs to fulfill its duty to protect consumers, not abuse their powers in ways the Congress never intended.”
Last month the American Medical Association, in adopting a new slate of drug policy positions, said that people “who are using kratom only for personal use should not face criminal consequences,” although the group added that the substance should be evaluated by authorities “for its appropriateness for sale and potential oversight via the Controlled Substances Act, before it can be marketed, purchased, or prescribed.”
GOP Congressman Pushes DEA Head For Update On Biden’s Marijuana Scheduling Review
Photo courtesy of Wikimedia/ThorPorre.
The post Former Trump Drug Czar Says Top Federal Officials Stopped FDA From Scheduling Kratom Amid Concern About Agency’s ‘Bias’ appeared first on Marijuana Moment.
